SAR-446422 is under clinical development by Sanofi and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) ...

Jackie Salvatore has served as undersheriff since 2022 when Krapf appointed her after he defeated Sheriff David Bartlett in the previous year’s election. Advertisement Article continues below ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

In a rare interview in 2023, the late Mulholland Drive director told BBC journalist Matthew Sweet about his defining work with composer Angelo Badalamenti. From the darkness of Mulholland Drive to ...

Salvatore Bazzano, age 97, of Rocky Hill, CT, passed away peacefully in his home on January 9, 2025. Born on September 26, 1927, in Hartford, CT, he was the son of the late Joseph and Melina ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Snapshot of the implementation used to generate figures and numerical results from the paper "Sharp Bounds for Continuous-Valued Treatment Effects with Unobserved ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform. Alloy is ...

The companies have teamed up to use Alloy’s AntiClastic Antisense platform. Credit: Bevan Goldswain via Getty Images. Sanofi has entered into a collaboration and license agreement with Alloy ...

The Company has received communication from its Registrar and Share Transfer Agent on loss of share certificates. Kindly refer to the enclosed file for details. The Company has approved issue of ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has ...